Drugs / 2-Iminobiotin
2-Iminobiotin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02836340 | May 2016 → Dec 2019 | brain hypoxia - ischemia, cardiac arrest | Academic Medical Center - University of Amsterdam | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01626924 | Jun 2012 → Oct 2014 | perinatal asphyxia | Neurophyxia B.V. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-Iminobiotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01626924 ↗ |
| Known as | 2-IB | “The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide...” NCT02836340 ↗1“2 Iminobiotin (2 IB) is an investigational medicinal product that is related to vitamin B7.” NCT01626924 ↗ |
| Known as | Guanidinobiotin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1233598 ↗ |
| Action | Inhibit | “a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).” NCT02836340 ↗ |
| Modality | Small molecule | — CHEMBL1233598 ↗ |
| Route | Intravenous | “It is administered as a solution for I.V.infusion through a central catheter.” NCT01626924 ↗ |